BCMA-directed CAR-T cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia

Blood 2026 Open access

Read full text
Authors: Jinhui Shu, Mei‐Yan Xu, Peiru Li, Wei Xie, Lin Liu, H Li, James Bruce Bussel, Yu Hu, Heng Mei
DOI: 10.1182/blood.2026035047
Cited by: 1

Abstract

This first clinical evaluation of BCMA CAR-T cell therapy in four patients with refractory primary ITP demonstrated manageable safety, rapid and sustained platelet recovery, and durable drug-free complete remission lasting up to 15 months, supporting further evaluation in larger studies.

Fields of Study & Subjects

CAR-T cell therapy research Platelet Disorders and Treatments Cutaneous lymphoproliferative disorders research

Publication details

Journal / source
Blood
Publisher
American Society of Hematology
Publication date
24 July 2026
Language
EN